dipyridamole has been researched along with Cerebral Hemorrhage in 15 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Cerebral Hemorrhage: Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Combination therapy with dipyridamole and clopidogrel in stroke prevention and long-term outcomes in aspirin-intolerant patients with acute myocardial infarction (AMI) and previous stroke are unknown." | 7.91 | Combination Therapy with Dipyridamole and Clopidogrel for Secondary Stroke Prevention in Aspirin-Intolerant Patients After Myocardial Infarction: Results of a Nationwide Case-Control Study. ( Chiang, CH; Huang, WC; Hung, CC; Kuo, FY; Liang, HL; Lin, KC; Liu, CP; Mar, GY; Tang, PL; Wang, MT; Yang, JS, 2019) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 7.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "Combination therapy with dipyridamole and clopidogrel in stroke prevention and long-term outcomes in aspirin-intolerant patients with acute myocardial infarction (AMI) and previous stroke are unknown." | 3.91 | Combination Therapy with Dipyridamole and Clopidogrel for Secondary Stroke Prevention in Aspirin-Intolerant Patients After Myocardial Infarction: Results of a Nationwide Case-Control Study. ( Chiang, CH; Huang, WC; Hung, CC; Kuo, FY; Liang, HL; Lin, KC; Liu, CP; Mar, GY; Tang, PL; Wang, MT; Yang, JS, 2019) |
| "In patients with ischemic stroke of non-cardioembolic origin, acetylsalicylic acid, clopidogrel, or a combination of acetylsalicylic acid and dipyridamole are recommended for the prevention of a recurrent stroke." | 3.81 | Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study. ( Carlson, N; Christiansen, CB; Gerds, TA; Gislason, G; Jørgensen, ME; Kristensen, SL; Numé, AK; Olesen, JB; Pallisgaard, J; Torp-Pedersen, C, 2015) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 3.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "Performance in patients with cerebral ischemia was poor." | 2.53 | Prediction models for intracranial hemorrhage or major bleeding in patients on antiplatelet therapy: a systematic review and external validation study. ( Algra, A; Greving, JP; Hilkens, NA, 2016) |
| "Dipyridamole treatment did not worsen frequency and size of cerebral microscopic bleeding." | 1.37 | Therapeutic modulation of cerebral microhemorrhage in a mouse model of cerebral amyloid angiopathy. ( Cribbs, DH; Fisher, M; Passos, GF; Quiring, D; Vasilevko, V; Ventura, C, 2011) |
| "We assessed the safety of thrombolysis under APs in 11,865 patients compliant with the European license criteria and recorded between 2002 and 2007 in the Safe Implementation of Treatments in Stroke (SITS) International Stroke Thrombolysis Register (SITS-ISTR)." | 1.36 | Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. ( Ahmed, N; Diedler, J; Ford, GA; Lees, KR; Luijckx, GJ; Overgaard, K; Ringleb, P; Soinne, L; Sykora, M; Uyttenboogaart, M; Wahlgren, N, 2010) |
| "Stroke is a devastating complication in patients with prosthetic valves, but characterization of its late occurrence from a large cohort is lacking." | 1.32 | Late incidence and determinants of stroke after aortic and mitral valve replacement. ( Bédard, PJ; Goldstein, WG; Hendry, PJ; Masters, RG; Mesana, TG; Pipe, AL; Rubens, FD; Ruel, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (20.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, MT | 1 |
| Liang, HL | 1 |
| Hung, CC | 1 |
| Tang, PL | 1 |
| Lin, KC | 1 |
| Chiang, CH | 1 |
| Kuo, FY | 1 |
| Yang, JS | 1 |
| Liu, CP | 1 |
| Mar, GY | 1 |
| Huang, WC | 1 |
| Takahashi, S | 1 |
| Mizuno, O | 1 |
| Sakaguchi, T | 1 |
| Yamada, T | 1 |
| Inuyama, L | 1 |
| Christiansen, CB | 1 |
| Pallisgaard, J | 1 |
| Gerds, TA | 1 |
| Olesen, JB | 1 |
| Jørgensen, ME | 1 |
| Numé, AK | 1 |
| Carlson, N | 1 |
| Kristensen, SL | 1 |
| Gislason, G | 1 |
| Torp-Pedersen, C | 1 |
| Hilkens, NA | 1 |
| Algra, A | 2 |
| Greving, JP | 1 |
| Selim, M | 1 |
| Diedler, J | 1 |
| Ahmed, N | 1 |
| Sykora, M | 1 |
| Uyttenboogaart, M | 1 |
| Overgaard, K | 1 |
| Luijckx, GJ | 1 |
| Soinne, L | 1 |
| Ford, GA | 1 |
| Lees, KR | 2 |
| Wahlgren, N | 1 |
| Ringleb, P | 1 |
| Fisher, M | 1 |
| Vasilevko, V | 1 |
| Passos, GF | 1 |
| Ventura, C | 1 |
| Quiring, D | 1 |
| Cribbs, DH | 1 |
| Flemming, KD | 1 |
| Link, MJ | 1 |
| Christianson, TJ | 1 |
| Brown, RD | 1 |
| Aslanyan, S | 1 |
| Fazekas, F | 1 |
| Weir, CJ | 1 |
| Horner, S | 1 |
| Ruel, M | 1 |
| Masters, RG | 1 |
| Rubens, FD | 1 |
| Bédard, PJ | 1 |
| Pipe, AL | 1 |
| Goldstein, WG | 1 |
| Hendry, PJ | 1 |
| Mesana, TG | 1 |
| Moussouttas, M | 1 |
| Biller, J | 1 |
| Martin, GJ | 1 |
| Koudstaal, PJ | 1 |
| van Gijn, J | 1 |
| Björk, VO | 1 |
| Henze, A | 1 |
| Browder, A | 1 |
| Browder, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Non-invasive Evaluation of Cerebrovascular Reactivity in Spontaneous Intracerebral Hemorrhage[NCT03815513] | Phase 1 | 60 participants (Anticipated) | Interventional | 2019-01-21 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for dipyridamole and Cerebral Hemorrhage
| Article | Year |
|---|---|
Prediction models for intracranial hemorrhage or major bleeding in patients on antiplatelet therapy: a systematic review and external validation study.
Topics: Algorithms; Anticoagulants; Aspirin; Brain Ischemia; Calibration; Cerebral Hemorrhage; Dipyridamole; | 2016 |
Cardiogenic cerebral embolism.
Topics: Anticoagulants; Aspirin; Cardiac Surgical Procedures; Cerebral Hemorrhage; Cerebral Infarction; Dipy | 1984 |
[Secondary prevention following cerebral ischemia: is monotherapy with acetylsalicylic acid still first choice?].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel | 1998 |
12 other studies available for dipyridamole and Cerebral Hemorrhage
| Article | Year |
|---|---|
Combination Therapy with Dipyridamole and Clopidogrel for Secondary Stroke Prevention in Aspirin-Intolerant Patients After Myocardial Infarction: Results of a Nationwide Case-Control Study.
Topics: Aged; Case-Control Studies; Cerebral Hemorrhage; Clopidogrel; Dipyridamole; Disease-Free Survival; D | 2019 |
Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Dipyridamole | 2014 |
Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Cohort Studies; | 2015 |
Antiplatelets for stroke prevention: implications of the PRoFESS trial.
Topics: Aspirin; Cerebral Hemorrhage; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Drug Therapy, | 2009 |
Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrh | 2010 |
Therapeutic modulation of cerebral microhemorrhage in a mouse model of cerebral amyloid angiopathy.
Topics: Animals; Cerebral Amyloid Angiopathy; Cerebral Hemorrhage; Dipyridamole; Disease Models, Animal; Fem | 2011 |
Use of antithrombotic agents in patients with intracerebral cavernous malformations.
Topics: Aged; Aspirin; Cerebral Hemorrhage; Dipyridamole; Female; Fibrinolytic Agents; Follow-Up Studies; He | 2013 |
Effect of blood pressure during the acute period of ischemic stroke on stroke outcome: a tertiary analysis of the GAIN International Trial.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Brain Isc | 2003 |
Late incidence and determinants of stroke after aortic and mitral valve replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aortic Valve; Aspirin; Atrial Fibrillation; Cerebral | 2004 |
Emerging therapies: ESPRIT.
Topics: Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clinical Trials as Topic; Dipyridamole; Drug Therapy, | 2007 |
Management of thrombo-embolism after aortic valve replacement with the Björk-Shiley tilting disc valve. Medicamental prevention with dicumarol in comparison with dipyridamole - acetylsalicylic acid. Surgical treatment of prosthetic thrombosis.
Topics: Adult; Aortic Valve; Aspirin; Cerebral Hemorrhage; Dicumarol; Dipyridamole; Drug Therapy, Combinatio | 1975 |
Prevention of stroke.
Topics: Age Factors; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Auscultation; Cerebral Angiograph | 1975 |